Three companies handle nearly 80% of the roughly 6.6 billion prescriptions dispensed in the United States in a year, and none of them is your health insurer. Understanding how pharmacy benefit managers work matters right now because open enrollment starts in a few weeks and the formulary you are about to accept was built by one of them. The part worth knowing is not that middlemen take a cut. It is that your share of a prescription is calculated from a price that stops being true about six weeks after you pay it.
Your coinsurance is calculated at the counter, on the list price. Your plan’s real cost is settled later, once the manufacturer’s rebate lands. Nobody goes back and reconciles the two, and you are on the wrong side of that.
Your pharmacy benefit is probably not run by your insurance company
Your medical card and your drug coverage usually come from different companies that happen to share a parent. The Federal Trade Commission’s July 2024 staff report on prescription drug middlemen found that the top three pharmacy benefit managers, Caremark Rx, Express Scripts, and OptumRx, processed nearly 80% of the roughly 6.6 billion prescriptions dispensed by US pharmacies in 2023. Add Humana Pharmacy Solutions, Prime Therapeutics, and MedImpact and you are above 90% of everything filled in the country.
Ownership is where this stops being trivia. Caremark belongs to CVS Health, Express Scripts to Cigna, and OptumRx to UnitedHealth Group, and all three parents own pharmacies as well. Fill a specialty prescription and the company that set the price, the company that pays the claim, and the company that hands you the bottle can be three subsidiaries of one corporation.
The manager itself does four jobs: it decides which drugs your plan covers and on what tier, builds the pharmacy network, processes the claim in the two seconds the pharmacist is waiting, and negotiates with manufacturers. The last one is where the money is.
The list price is built so it can be discounted
A manufacturer sets a list price. Then it offers a rebate, paid after the fact, in exchange for favorable formulary placement. A drug on tier 2 with no prior authorization sells far more than the same drug on tier 4 behind a paperwork wall, so that placement is worth paying for.
A manufacturer that wants to pay a large rebate has to start from a large list price, which is why list prices keep climbing even in years when net prices flatten. And because the rebate is contingent, the condition attached to it is often that a cheaper competitor gets excluded or buried behind prior authorization. Formulary exclusion lists are the visible edge of that bargaining. Drug Channels reported that Express Scripts added 129 new exclusions to its National Preferred formulary for 2026, up from 19 the year before, while CVS Caremark added 16 and OptumRx added 12.
An exclusion is not a medical judgment about your prescription. It is the outcome of a negotiation you were not party to, and it is why the drug you took all last year can stop being covered on January 1 with no change in your health.
How pharmacy benefit managers work when they also own the pharmacy
Vertical integration adds a second revenue line that has nothing to do with rebates. The FTC’s second interim report, issued in January 2025, examined 51 specialty generic drugs dispensed between 2017 and 2022 and found that pharmacies affiliated with the big three generated more than $7.3 billion in dispensing revenue above the National Average Drug Acquisition Cost. More than 94% of that came from cancer, multiple sclerosis, transplant, HIV, and pulmonary hypertension medicines. Tadalafil, a generic used for pulmonary hypertension, was marked up more than 7,700% in 2022.
The same report identified roughly $1.4 billion in spread pricing on those 51 drugs alone between 2017 and 2021. Spread pricing is simple to describe: the plan is billed one amount, the pharmacy is reimbursed a smaller amount, and the difference stays with the middleman. It looks like a discount on the plan’s invoice because the plan never sees the pharmacy’s side of the ledger.
Your coinsurance is calculated on a number that expires
Say your plan covers a brand drug at a negotiated price of $600 a month and charges 30% coinsurance. You hand over $180 at the register. Your plan pays the remaining $420. Six weeks later the manufacturer’s 30% rebate arrives, $180, and the plan’s true cost for that fill drops to $240.
Do the division. The drug actually cost $420 in real money. You paid $180 of it, which is 43% of the cost, not the 30% printed in your benefits summary. Over twelve months you pay $2,160 while the plan nets $2,880 on a drug whose net annual cost is $5,040. Your coinsurance percentage was applied to the pre-rebate number, and the rebate was applied to somebody else’s.
Deductibles make it sharper. During the months before you hit your deductible you pay the full $600, and the plan still collects the $180 rebate on a claim it paid nothing toward. This is also why the same drug can cost wildly different amounts in January and July, a pattern we unpack in our explainer on how out-of-pocket maximums work.
Sometimes the cash price is the lower price
The strangest consequence is that insurance can make a prescription more expensive. Researchers at the USC Schaeffer Center analyzed 9.5 million pharmacy claims and published the result in JAMA in 2018. In about 23% of them, 2.2 million claims, the patient’s copay exceeded what the insurer reimbursed the pharmacy. The average overpayment was $7.69. For brand drugs it averaged $13.46, for generics $7.32, and generics were the more common case at 28% of fills versus 6% for brands.
A household filling two dozen prescriptions a year would expect five or six of them to be overpayments, somewhere around $42. Small money, but it is money moving in the direction nobody would predict.
That study used 2013 claims, and one thing has genuinely changed since: Congress banned pharmacy gag clauses in October 2018, so a pharmacist is now free to tell you when the cash price is lower. They usually will not volunteer it, because the register does not prompt them. Asking is a one-sentence habit worth acquiring for generics in particular.
Congress delinked the rebates, and your plan will not feel it until 2028
On February 3, 2026, the Consolidated Appropriations Act was signed into law with the most substantial pharmacy benefit manager reform Congress has passed. As reported by the American Journal of Managed Care, it requires Medicare Part D managers to be paid flat administrative fees rather than a share of list prices or rebates, to pass through 100% of manufacturer remuneration to payers, and to report gross and net spending semiannually, with CMS able to impose penalties.
The scope is narrower than the headlines suggested. It restructures Part D, and the core delinking provisions do not take effect until January 2028. If your drug coverage comes through an employer, this law does not reach your plan, though the Department of Labor has proposed rules that would extend similar disclosure duties to self-insured group plans. Medicare enrollees have their own timeline, which we cover in our piece on the 2026 Part D redesign.
Meanwhile the carriers have moved on their own. OptumRx committed to full rebate pass-through starting January 2026, Express Scripts announced it would end rebate retention, and Caremark has offered pass-through contracts since 2019. Pass-through to the payer is not the same as pass-through to you at the counter, and that distinction is the one to watch. Knowing how pharmacy benefit managers work does not change your plan’s design, but it does tell you which question to ask during open enrollment: whether your employer’s contract applies the rebate at the point of sale, or keeps it. The answer changes your bill by hundreds of dollars and is written down somewhere in your plan’s pharmacy agreement.